Enterprise Value
193.1M
Cash
343M
Avg Qtr Burn
-29.92M
Short % of Float
0.00%
Insider Ownership
8.45%
Institutional Own.
76.89%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
obe-cel (AUTO1) (CD19) Details Acute lymphoblastic leukemia, Cancer, Blood cancer | BLA Submission | |
AUTO4 Details Peripheral T cell cancer | Phase 1/2 Data readout | |
obe-cel (AUTO1) (CD19) Details Non-Hodgkin lymphoma, Cancer, Leukemia, Lymphoma, Chronic lymphocytic leukemia | Phase 1 Data readout | |
obe-cel (AUTO1) (CD19) Details Primary CNS lymphoma (central nervous system) | Phase 1 Data readout | |
AUTO8 (BMCA & CD19) Details Multiple myeloma | Phase 1 Data readout | |
AUTO1/22 (CD19 & CD22) Details Cancer, Leukemia, Acute lymphoblastic leukemia | Phase 1 Update | |
AUTO5 Details T-cell lymphoma | Phase 1 Initiation | |
AUTO6NG Details Solid tumor/s, Neuroblastoma | Phase 1 Initiation | |
AUTO3 (CD19, CD22) Details Lymphoma, Diffuse large B cell lymphoma, Cancer | Failed Discontinued |